Agenus Inc. (NASDAQ:AGEN) Given Consensus Rating of “Hold” by Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN) have earned a consensus rating of “Hold” from the five analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $26.3333.

A number of equities analysts have issued reports on AGEN shares. HC Wainwright reiterated a “buy” rating and set a $25.00 price target (down from $30.00) on shares of Agenus in a research report on Tuesday, August 11th. Weiss Ratings lowered shares of Agenus from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, August 21st. B. Riley Financial reaffirmed a “buy” rating and issued a $14.00 price target (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Wall Street Zen lowered Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. Finally, Chardan Capital assumed coverage on shares of Agenus in a research note on Friday. They set a “buy” rating and a $40.00 target price on the stock.

Agenus Stock Up 0.1%

Shares of AGEN stock opened at $7.22 on Friday. The stock has a market cap of $326.06 million, a PE ratio of 2.80 and a beta of 1.38. Agenus has a 52-week low of $2.71 and a 52-week high of $8.85. The business has a 50-day simple moving average of $6.99 and a 200-day simple moving average of $4.73.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a negative return on equity of 47.68% and a net margin of 69.33%.The company had revenue of $34.52 million during the quarter, compared to analysts’ expectations of $34.00 million. Sell-side analysts anticipate that Agenus will post -0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agenus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGEN. Globeflex Capital L P acquired a new position in Agenus in the second quarter valued at about $1,281,000. Bank of New York Mellon Corp acquired a new stake in shares of Agenus in the second quarter valued at $311,000. Bank of America Corp DE lifted its stake in Agenus by 796.7% during the 1st quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock worth $397,000 after acquiring an additional 105,536 shares in the last quarter. Ovata Capital Management Ltd acquired a new position in Agenus in the 4th quarter valued at about $97,000. Finally, Redwood Family Wealth LLC purchased a new stake in Agenus during the fourth quarter worth about $44,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. Its research programs are designed to activate and direct the immune system against tumors, with an emphasis on therapies that may address immune resistance and improve responses in difficult-to-treat cancers.

The company’s pipeline has included checkpoint inhibitors, cancer vaccines, immune-stimulating adjuvants, bispecific antibodies and other antibody-based therapies.